

Drug	Schedule	Drug	Schedule
Cathinone (1235)	I	3-Methylfentanyl (9813)	I
Methcathinone (1237)	I	Alpha-Methylfentanyl (9814)	I
N-Ethylamphetamine (1475)	I	Acetyl-alpha-methylfentanyl (9815)	I
N,N-Dimethylamphetamine (1480)	I	Beta-hydroxyfentanyl (9830)	I
Aminorex (1585)	I	Beta-hydroxy-3-methylfentanyl (9831)	I
4-Methylaminorex (cis isomer) (1590)	I	Alpha-Methylthiofentanyl (9832)	I
Gamma hydroxybutyric acid (2010)	I	3-Methylthiofentanyl (9833)	I
Methaqualone (2565)	I	Thiofentanyl (9835)	I
Alpha-Ethyltryptamine (7249)	I	Amphetamine (1100)	II
Lysergic acid diethylamide (7315)	I	Methamphetamine (1105)	II
Tetrahydrocannabinols (7370)	I	Phenmetrazine (1631)	II
Mescaline (7381)	I	Methylphenidate (1724)	II
3,4,5-Trimethoxyamphetamine (7390)	I	Ambobarbital (2125)	II
4-Bromo-2,5-dimethoxyamphetamine (7391)	I	Pentobarbital (2270)	II
4-Bromo-2,5-dimethoxyphenethylamine (7392)	I	Secobarbital (2315)	II
4-Methyl-2,5-dimethoxyamphetamine (7395)	I	Glutethimide (2550)	II
2,5-Dimethoxyamphetamine (7396)	I	Nabilone (7379)	II
2,5-Dimethoxy-4-ethylamphetamine (7399)	I	1-Phenylcyclohexylamine (7460)	II
3,4-Methylenedioxyamphetamine (7400)	I	Phencyclidine (7471)	II
5-Methoxy-3,4-methylenedioxyamphetamine (7401)	I	1-Piperidinocyclohexanecarbonitrile (8603)	II
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)	I	Alphaprodine (9010)	II
3,4-Methylenedioxy-N-ethylamphetamine (7404)	I	Cocaine (9041)	II
3,4-Methylenedioxymethamphetamine (7405)	I	Codeine (9050)	II
4-Methoxyamphetamine (7411)	I	Dihydrocodeine (9120)	II
Bufotenine (7433)	I	Oxycodone (9143)	II
Diethyltryptamine (7434)	I	Hydromorphone (9150)	II
Dimethyltryptamine (7435)	I	Diphenoxylate (9170)	II
Psilocybin (7437)	I	Benzoylcegonine (9180)	II
Psilocyn (7438)	I	Ethylmorphine (9190)	II
Acetyldihydrocodeine (9051)	I	Hydrocodone (9193)	II
Benzylmorphine (9052)	I	Levomorphine (9210)	II
Codeine-N-oxide (9053)	I	Levorphanol (9220)	II
Dihydromorphine (9145)	I	Isomethadone (9226)	II
Heroin (9200)	I	Meperidine (9230)	II
Hydromorphenol (9301)	I	Methadone (9250)	II
Methyldihydromorphine (9304)	I	Methadone-intermediate (9254)	II
Morphine-N-oxide (9307)	I	Dextropropoxyphene, bulk (non-dosage forms) (9273)	II
Normorphine (9313)	I	Morphine (9300)	II
Pholcodine (9314)	I	Thebaine (9333)	II
Acetylmethadol (9601)	I	Levo-alphaacetylmethadol (9648)	II
Allylprodine (9602)	I	Oxymorphone (9652)	II
Alphacetylmethadol except levo-alphaacetylmethadol (9603)	I	Noroxymorphone (9668)	II
Alphameprodine (9604)	I	Racemethorphan (9732)	II
Alphamethadol (9605)	I	Alfentanil (9737)	II
Betacetylmethadol (9607)	I	Sufentanil (9740)	II
Betameprodine (9608)	I	Fentanyl (9801)	II
Betamethadol (9609)	I		
Betaprodine (9611)	I		
Hydroxypethidine (9627)	I		
Noracymethadol (9633)	I		
Norlevorphanol (9634)	I		
Normethadone (9635)	I		
Trimeperidine (9646)	I		
Phenomorphan (9647)	I		
Para-Fluorofentanyl (9812)	I		

The company plans to manufacture small quantities of the listed controlled substances to make reference standards for distribution to their customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCD) and must be filed no later than December 13, 2004.

Dated: September 28, 2004.

William J. Walker,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 04-23053 Filed 10-13-04; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under 21 U.S.C. 952(a)(2)(B) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on June 29, 2004, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78664, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances listed below:

Drug	Schedule
Cathinone (1235)	I
Methcathinone (1237)	I
N-Ethylamphetamine (1475)	I
Gamma hydroxybutyric acid (2010)	I
Ibogaine (7260)	I
Tetrahydrocannabinols (7370)	I
Mescaline (7381)	I
4-Bromo-2,5-dimethoxyamphetamine (7391)	I
4-Bromo-2,5-dimethoxyphenethylamine (7392)	I
4-Methyl-2,5-dimethoxyamphetamine (7395)	I
2,5-Dimethoxyamphetamine (7396)	I
3,4-Methylenedioxyamphetamine (7400)	I
3,4-Methylenedioxymethamphetamine (7404)	I
3,4-Methylenedioxymethamphetamine (7405)	I
4-Methoxyamphetamine (7411)	I
Psilocybin (7437)	I
Psilocyn (7438)	I
Etorphine (9056)	I
Heroin (9200)	I
Pholcodine (9314)	I
Amphetamine (1100)	II
Methamphetamine (1105)	II
Amobarbital (2125)	II
Pentobarbital (2270)	II
Cocaine (9041)	II

Drug	Schedule
Codeine (9050)	II
Dihydrocodeine (9120)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Benzoyllecgonine (9180)	II
Ethylmorphine (9190)	II
Meperidine (9230)	II
Methadone (9250)	II
Dextropropoxyphene, bulk (non-dosage forms) (9273)	II
Morphine (9300)	II
Thebaine (9333)	II
Levo-alphaacetylmethadol (9648) ..	II
Oxymorphone (9652)	II

The company plans to import small quantities of the listed controlled substances for the manufacture of analytical reference standards.

Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections or requests for hearing may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCD) and must be filed no later than November 15, 2004.

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f).

As noted in a previous notice published in the **Federal Register** on September 23, 1975, (40 FR 43745-46), all applicants for registration to import a basic class of any controlled substances in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied.

Dated: September 28, 2004.

William J. Walker,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 04-23054 Filed 10-13-04; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated March 29, 2004, and published in the **Federal Register** on April 29, 2004, (69 FR 23537-23538), Cody Laboratories, Inc., 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance in Schedule II.

The company plans to manufacture the product in bulk to distribute to its customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cody Laboratories, Inc. to manufacture the basic class of controlled substance listed is consistent with the public interest at this time. DEA has investigated Cody Laboratories, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: September 28, 2004.

William J. Walker,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 04-23055 Filed 10-13-04; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated April 9, 2004, and published in the **Federal Register** on April 26, 2004, (69 FR 22566), Penick, Corporation, 158 Mount Olivet Avenue, Newark, New Jersey 07114, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances:

Drug	Schedule
Cocaine (9041)	II
Codeine (9050)	II
Dihydrocodeine (9120)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Diphenoxylate (9170)	II
Ecgonine (9180)	II
Hydrocodone (9193)	II
Morphine (9300)	II
Thebaine (9333)	II
Oxymorphone (9652)	II

The company plans to manufacture bulk controlled substances and non-controlled substance flavor extracts.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Penick Corporation to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Penick Corporation to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: September 28, 2004.

William J. Walker,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 04-23060 Filed 10-13-04; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

Notice dated June 1, 2004, and published in the **Federal Register** on June 16, 2004, (69 FR 33666), Siegfried (USA), Inc., Industrial Park Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Methadone Intermediate (9254), a basic class of controlled substance in Schedule II.

The company plans to manufacture the listed controlled substance for